Physiologic Changes In Pregnancy: Effect on Drug Disposition

Center for Drug Evaluation and Research, U.S. Food and Drug Administration

horizonal rule

Physiologic Changes In Pregnancy: Effect on Drug Disposition

Click here to start

Table of Contents

Physiologic Changes In Pregnancy: Effect on Drug Disposition

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Cardiovascular System Changes

Cardiovascular System Changes

Regional Blood Flow Changes

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Respiratory Changes

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Albumin Concentration During Pregnancy

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Enzymatic Activity Changes

CYP2D6 Activity

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Renal Clearance Changes

Pregnancy Physiology Potentially Affecting Pharmacokinetics

Gastrointestinal Changes

Maternal Physiologic Changes Altering PK of Drugs

Maternal Physiologic Changes Altering PK of Drugs

Maternal Physiologic Changes Altering PK of Drugs

Carbamazepine Plasma Concentrations During Pregnancy

Phenytoin Plasma Concentrations in Pregnancy

Tobramycin Pharmacokinetics

Enoxaprin Pharmacokinetics during Pregnancy

Maternal Physiologic Changes Altering PK of Drugs

Oral Ampicllin Pharmacokinetics in Pregnancy

PK of Oral Valacyclovir & Acyclovir

Peripartum Pharmacologic Considerations

Pharmacokinetics of Cefuroxime in Pregnancy

Postpartum PK Considerations

Postpartum Clindamycin Pharmacokinetics

Technical Considerations

Drug Studies for Pregnancy

Author: Marilynn Frederiksen

Download presentation source

Last update: July 11, 2005



	CDER Home Page \| CDER Site Info \| Contact CDER \| What's New @ CDER FDA Home Page \| Search FDA Site \| FDA A-Z Index \| Contact FDA \| Privacy \| Accessibility \| HHS Home Page FDA/Center for Drug Evaluation and Research